The inflammasome NLRP3 is upregulated in DMD, and its ablation attenuates the dystrophic phenotype, suggesting that NLRP3 inhibitors may have a therapeutic potential for muscle inflammation and myopathies. The gene discussed is NLRP3; the disease is Duchenne muscular dystrophy.